Collegium Pharmaceutical (COLL) Return on Capital Employed (2015 - 2026)

Collegium Pharmaceutical's Return on Capital Employed history runs 12 years deep, the most recent figure standing at 15.49% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 324.0% year-over-year to 15.49% in Q1 2026; TTM through Mar 2026 was 15.49%, a 324.0% increase from a year earlier, with the FY2025 full-year figure at 14.72%, down 428.0% from the prior year.
• Return on Capital Employed improved to 15.49% in Q1 2026 per COLL's latest filing, from 15.07% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 32.74% in Q2 2024 and bottomed at 2.28% in Q1 2022.
• The 5-year median for Return on Capital Employed is 13.69% (2025), against an average of 13.18%.
• Across the five-year window, Return on Capital Employed jumped 2086 bps in 2024 and slumped 2143 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 4.42% in 2022, then surged by 438 bps to 23.77% in 2023, then sank by 37 bps to 14.9% in 2024, then rose by 1 bps to 15.07% in 2025, then gained by 3 bps to 15.49% in 2026.
• Per Business Quant, the three latest COLL Return on Capital Employed figures stand at 15.49% (Q1 2026), 15.07% (Q4 2025), and 13.69% (Q3 2025).